文献速递衰弱、肌少症与跌倒老年慢病共病管理

低剂量阿司匹林对社区老年人衰弱表型与衰弱指数的影响:ASPREE研究

The Effect of Low-Dose Aspirin on Frailty Phenotype and Frailty Index in Community-Dwelling Older Adults in the ASPirin in Reducing Events in the Elderly Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2022-01-01

中位4.7年随访中,阿司匹林未改变新发Fried衰弱(HR 1.04,95%CI 0.96-1.13)或衰弱指数(HR 1.03,95%CI 0.97-1.09)的风险,衰弱比例和连续评分轨迹亦无差异。

要点

  • 健康老年人晚年起始低剂量阿司匹林不降低新发衰弱风险。
  • 阿司匹林对衰弱指数和Fried衰弱表型的影响均无统计学差异。
  • 衰弱比例及随时间变化的连续衰弱评分轨迹在两组间无差异。

核心结论

  • 在健康老年人中晚年起始低剂量阿司匹林不降低新发衰弱风险或改变衰弱轨迹。

主要发现

  • 与安慰剂相比,阿司匹林未改变新发衰弱风险(Fried衰弱HR 1.04,95%CI 0.96-1.13;衰弱指数HR 1.03,95%CI 0.97-1.09)。
  • 被分类为衰弱个体的比例及连续衰弱评分随时间轨迹在阿司匹林组与安慰剂组间无差异。
  • 结果在一系列亚组中一致。

关键数值与推荐

  • 衰弱为预设研究终点,采用改良Fried衰弱定义和基于缺陷累积模型的衰弱指数定义。
  • 采用竞争风险Cox比例风险模型比较阿司匹林与安慰剂组至新发衰弱的时间。
  • 敏感性分析纳入缺失数据插补与不插补的衰弱数据。

临床怎么用

  • 不应以预防衰弱为目的对健康老年人起始低剂量阿司匹林。
  • 老年衰弱风险管理需关注其他可干预因素,而非阿司匹林。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is associated with chronic inflammation, which may be modified by aspirin. The purpose of this study was to determine whether low-dose aspirin reduces incident frailty in healthy older adult participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. METHODS: In the United States and Australia, 19 114 community-dwelling individuals aged ≥70 and older (U.S. minorities ≥65 years) and free of overt cardiovascular disease, persistent physical disability, and dementia were enrolled in ASPREE, a double-blind, placebo-controlled trial of 100-mg daily aspirin versus placebo. Frailty, a prespecified study end point, was defined according to a modified Fried frailty definition (Fried frailty) and the frailty index based on the deficit accumulation model (frailty index). Competing risk Cox proportional hazard models were used to compare time to incident frailty by aspirin versus placebo. Sensitivity analysis was conducted to include frailty data with and without imputation of missing data. RESULTS: Over a median 4.7 years, 2 252 participants developed incident Fried frailty, and 4 451 had incident frailty according to the frailty index. Compared with placebo, aspirin treatment did not alter the risk of incident frailty (Fried frailty hazard ratio [HR]: 1.04, 95% confidence interval [CI] 0.96-1.13; frailty index HR: 1.03, 95% CI 0.97-1.09). The proportion of individuals classified as frail, and the trajectory in continuous frailty scores over time, were not different between the aspirin and placebo treatment groups. The results were consistent across a series of subgroups. CONCLUSIONS: Low-dose aspirin use in healthy older adults when initiated in older ages does not reduce risk of incident frailty or the trajectory of frailty.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Espinoza SE, Woods RL, Ekram ARMS, et al. The Effect of Low-Dose Aspirin on Frailty Phenotype and Frailty Index in Community-Dwelling Older Adults in the ASPirin in Reducing Events in the Elderly Study. J Gerontol A Biol Sci Med Sci. 2022. PMID: 34758073. doi:10.1093/gerona/glab340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。